Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shionogi-ViiV

- PMLiVE

EMA refuses to back Pfizer’s Xeljanz in rheumatoid arthritis

Surprise after approvals in US and Japan

- PMLiVE

GSK sees sales drop but respiratory remains a bright spot

Profit also down in Q1 as Europe and US remain challenging for pharma and vaccines

- PMLiVE

GSK accused of delaying generic Seroxat in UK

Could be fined 10 per cent of global turnover if found to have infringed competition law

- PMLiVE

US shortage of GSK’s restless legs syndrome treatment Horizant

FDA blames contract manufacturer delays

- PMLiVE

GSK buoyed by FDA panel backing for Advair successor

Committee votes in favour of Breo’s use in respiratory condition COPD

- PMLiVE

First efficacy data for GSK/Prosensa’s muscular dystrophy candidate positive

Ups ante in race against Sarepta Therapeutics to market first Duchenne muscular dystrophy drug

- PMLiVE

GSK partners with Singapore research agency on emerging markets

Will work with A*STAR’s Institute of Chemical and Engineering to research reformulated medicines

- PMLiVE

Pharma companies partner with Japanese government

GHIT Fund will support development of medicines for infectious diseases in developing countries

- PMLiVE

Pfizer enters $210m+ nanomedicines deal with Bind

Will use Accurin technology to develop highly selective medicines

- PMLiVE

Pfizer partners with hospital to research medicines for children

Children’s Hospital of Philadelphia joins CTI translational research network

- PMLiVE

GSK’s four-strain flu vaccine approved in Germany and UK

Will be sold as Influsplit Tetra in Germany and Fluarix Tetra in the UK

- PMLiVE

Pfizer’s Bosulif gets conditional green light for CML in Europe

Follows US approval last year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links